16.19.20.42 PRESCRIPTION REQUIREMENTS:

G. A pharmacy employee must verify the identity of the patient or the patient’s representative who is receiving a prescription for a controlled substance listed in Schedule II, III, or IV, before it is delivered. Acceptable identification means a current state issued driver’s license, including photo, or other current government issued photo identification of the person presenting said identification. The identification type (e.g. driver’s license, identification card, passport etc.), number, of the government issued identification and the name imprinted on that identification, and state must be recorded in a manner to be determined by a written policy developed by the pharmacist-in-charge. Exceptions are, a new controlled substance prescription filled for a patient known to the pharmacist or pharmacist intern, whose identification has already been documented in a manner determined by a written policy developed by the pharmacist-in-charge; a controlled substance prescription filled for home delivery; or a controlled substance prescription filled for and delivered to a licensed facility.

16.19.20.42 PRESCRIPTION REQUIREMENTS:

F. A pharmacist may dispense directly a controlled substance listed in Schedule III or IV, which is a prescription drug as determined under the New Mexico Drugs and Cosmetics Act, only pursuant to either a written prescription signed by a practitioner or a facsimile of a written, signed prescription transmitted by the practitioner or the practitioner’s agent to the pharmacy or pursuant to an oral prescription made by an individual practitioner and promptly reduced to written form by the pharmacist containing all information required for a prescription except the signature of the practitioner. A new telephone prescription for any Schedule III, IV, or V opiate shall not exceed a ten day supply, based on the directions for use, and cannot be refilled. Verbal refill authorizations and clarifications to existing prescriptions are exempt from this requirement. A telephone order for a new therapy for an opiate listed in Schedule III, IV, or V, shall not exceed a ten day supply, based on the directions for use, unless a written prescription is on file at this pharmacy for the same opiate within the past six months. A telephone order for this new opiate therapy may not be refilled.

16.19.20.42 PRESCRIPTION REQUIREMENTS:

G. A pharmacy employee must verify the identity of the patient or the patient’s representative before a new prescription for a controlled substance listed in Schedule II, III, or IV, before it is delivered. Acceptable identification means a current state issued driver’s license, including photo, or other current government issued photo identification of the person presenting said identification. The identification type (e.g. driver’s license, identification card, passport etc.), number, of the government issued identification and the name imprinted on that identification, and state must be recorded in a manner to be determined by a written policy developed by the pharmacist-in-charge. Exceptions are, a new controlled substance prescription filled for a patient known to the pharmacist or pharmacist intern, whose identification has already been documented in a manner determined by a written policy developed by the pharmacist-in-charge; a controlled substance prescription filled for home delivery; or a controlled substance prescription filled for and delivered to a licensed facility.


16.19.20.20 INVENTORY RECORDS:

A. All registrants are required to keep inventory and procurement records.

B. All registrants shall comply with the following inventory requirements: Schedule I, II, III, IV and V Annual Inventory

C. The annual inventory date shall be May 1 for the initial inventory by the registrant or on the registrant’s regular general physical inventory date, provided that date does not vary by more than 6 months before or after May 1. The registrant shall notify the board of pharmacy of the date on which the annual inventory will be taken, if different from May 1. The actual taking of the inventory should not vary more than four (4) days from the annual inventory date. The inventory shall document being taken either as of the opening or as of the close of business activity, the inventory date and time, and shall be entered on the inventory record.
D. Controlled substances added to the Controlled Substances Act after date of enactment, which substance was, immediately prior to that date, not listed on any schedule, every registrant who possesses that substance shall take an inventory of all stock of the substance on hand and file this record with the other inventory records as required.

E. Upon the change of a pharmacist-in-charge, an inventory of all controlled substances shall be taken within 72 hours, by the new pharmacist-in-charge. The inventory shall be taken either as of the opening or as of the close of business activity on the inventory date, and such time and date taken shall be entered on the inventory record.

F. Upon transfer of ownership of a pharmacy, an inventory of all controlled substances shall be taken by the pharmacist-in-charge. The inventory shall be taken either as of the opening or as of the close of business activity on the inventory date, and such time and date taken shall be entered on the inventory record.

16.19.20.45 PRESCRIPTION REFILL REQUIREMENTS:

A. Prescriptions for any controlled substance Schedule III or IV substances shall not be filled or refilled more than six (6) months after the date of issue. or be refilled more than five (5) times unless renewed by the practitioner and a new prescription is placed in the pharmacy files.

B. Prescriptions for Schedule III, IV, or V controlled substances shall not be filled or refilled more than six (6) months after the date of issue or be refilled more than five (5) times unless renewed by the practitioner and a new prescription is placed in the pharmacy files.

(1) Controlled substance prescriptions dispensed directly to a patient shall not be refilled before 75% of the prescription days’ supply has passed, unless the practitioner authorizes the early refill, which must be documented by the pharmacist.

(2) Controlled substance prescriptions delivered to a patient indirectly (as mail order) to a patient shall not be refilled before 66% of a 90 day supply has passed or 50% of a 30 day supply has passed, unless the practitioner authorizes the early refill, which must be documented by the pharmacist.

B. Schedule V prescriptions may be refilled only as expressly authorized by the prescribing physician on the prescription. If no such authorization is given, the prescription may not be refilled.

16.19.20.45 PRESCRIPTION FILL AND REFILL REQUIREMENTS:

A. Prescriptions for Schedule II controlled substances shall not be filled more than six (6) months after the date of issue.

B. Prescriptions for Schedule III or IV controlled substances shall not be filled or refilled more than six (6) months after the date of issue or be refilled more than five (5) times unless renewed by the practitioner and a new prescription is placed in the pharmacy files.

(1) Controlled substance prescriptions dispensed directly to a patient shall not be refilled before 75% of the prescription days’ supply has passed, unless the practitioner authorizes the early refill, which must be documented by the pharmacist.

(2) Controlled substance prescriptions delivered to a patient indirectly (as mail order) to a patient shall not be refilled before 66% of a 90 day supply has passed or 50% of a 30 day supply has passed, unless the practitioner authorizes the early refill, which must be documented by the pharmacist.

B. Schedule V prescriptions may be refilled only as expressly authorized by the prescribing physician on the prescription. If no such authorization is given, the prescription may not be refilled.
A. OPIATES, unless specifically exempt or unless listed in another schedule, any of the following opiates, including its' isomers, esters, ethers, and salts is possible within the specific chemical designation.

1. Acetylmethadol
2. Allylprodine
3. Alphacetylmethadol
4. Alphameprodine
5. Alphamethadol
6. Alpha-methyl fentanyl
7. Benzethidine
8. Betacetylmethadol
9. Betameprodine
10. Betamethadol
11. Betaprodine
12. Clonitazene
13. Desmethytramadol
14. Dextromoramide
15. Diampromide
16. Diethylthiambutene
17. Dimethylthiambutene
18. Difenoxy
19. Dimenoxadol
20. Dimephtanol
21. Dimethylthiambutene
22. Dioxaphetyl Butyrate
23. Dipipanone
24. Ethylmethylthiambutene
25. Etonitazene
26. Etoxeridine
27. Furethidine
28. Hydroxypethidine
29. Ketobemidone
30. Levomoramide
31. Levophenacylmorphan
32. Morheridine
33. Noracymethadol
34. Norlevorphanol
35. Normethadone
36. Norpipanone
37. Phenadoxone
38. Phenampramide
39. Phenomorphan
40. Phenoperidine
41. Piritramide
42. Proheptazine
43. Properidine
44. Propiram
45. Racemoramide
46. Tildine
47. Trimetperidine
Acetorphine
Acetyl dihydrocodeine
Benzyl morphine
Codeine methylbromide
Codeine-N-Oxide
Cyprenorphine
Desomorphine
Dehydro morphine
Etorphine
Heroin
Hydromorphinol
Methyldesorphine
Methyldihydromorphine
Morphine methylbromide
Morphine methylsulfonate
Morphine-N-Oxide
Myrophine
Nicocodeine
Nicomorphine
Normorphine
Pholcodine
Thebacon
Drotebanol
Beta-Hydroxy-3-Methylfentanyl
3-Methylthiofentanyl
Acetyl-Alpha-Methyl fentanyl
Alpha-Methylthiofentanyl
Beta-hydroxfentanyl
Para-Fluoro fentanyl
Thiofentanyl
6-acetylmorphine (6AM)
Acetyl fentanyl
Butyryl fentanyl
Betahydroxythiofentanyl
Furanyl fentanyl
AH-7921 (3,4-dichloro-N-((1-dimethylamino)cyclohexyl)methyl]benzamide)
U47700 (trans-3,4-dichloro-N-(2-(dimethylamino)cyclohexyl)-N-methylbenzamide)
MT-45 ((1-(4-Nitrophenylethyl)piperidylidene-2-(4-chlorophenyl)sulfonamide))
W-15 (4-chloro-N-[1-(2-phenylethyl)-2-piperidinylidene]-benzenesulfonamide)
W-18 ((1-(4-Nitrophenylethyl)piperidylidene-2-(4-chlorophenyl)sulfonamide)

C. HALLUCINOGENIC SUBSTANCES: Unless specifically exempt or unless listed in another schedule, any material, compound, mixture or preparation, which contains any quantity of the following hallucinogenic substances, or which contains any of its’ salts, isomers, and salts of isomers whenever the existence of such salts, isomers and salts of isomers is possible within the specific chemical designation (for purpose of this sub-section only, the term “isomers” includes the optical position, and geometric isomers).

3,4 -methylenedioxymethamphetamine
5 - methoxy - 3,4-methylenedioxyamphetamine
3,4,5 -trimethoxyamphetamine
Bufotenine
Diethyltryptamine; DET
Dimethyltryptamine; DMT
4-methyl-2,5-dimethoxyamphetamine; DOM or STP
Lysergic acid amide
Lysergic acid diethylamide
Marijuana
Mescaline
Peyote
N-ethyl-3-piperidyl benzilate
N-methyl-3-piperidyl benzilate
Psilocybin
Psilocyn
Tetrahydrocannabinols
Parahexyl (synthetic analog of delta-9-tetrahydrocannabinol (THC) an active ingredient of cannabis)
Hashish
2, 5 -dimethoxyamphetamine; 2, 5-DMA
4-bromo-2, 5-dimethoxy-amphetamine; 2,5-DMA
4-methoxyamphetamine; PMA
Ethylamine N-ethyl-1-phenylcyclohexylamine (PCE)
Pyrrolidine 1-(1-phenylcyclohexyl)-pyrrolidine (PCPy), (PHP) analog of the drug phencyclidine
Thiophene (analog of phencyclidine) TCP or TPCP
Alpha-ethyltryptamine
2, 5-dimethoxy-4-ethylamphetamine
Ibogaine
2, 5 dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7)
Alpha-methyltryptamine (AMT)
5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT)
2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe)
2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe)
2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe)
Synthetic cannabinoids: Unless specifically exempted or unless listed in another schedule, any material, compound, mixture of preparation which contains any quantity of the following synthetic cannabinoids which demonstrates binding activity to the cannabinoid receptor or analogs or homologs with binding activity:
(a) CP 55,244 ((hydroxymethyl)-4-[2-hydroxy-4-(2-methyloctan-2-yl)phenyl] 1,2,3,4,4a,5,6,7,8a-decahydronaphthalen-2-ol)
(b) CP 55,940 (5-hydroxy-2-(3-hydroxypropyl) cyclohexyl-5-(2-methyloctan-2-yl)phenol)
(c) JWH-081 (1-pentyl-3-[1-(4-methoxynaphthoyl)]indole)
(d) JWH-122 (1-pentyl-3-(4-methyl-1-naphthoyl)indole)
(e) JWH-133 3-(1,1-dimethylbutyl)-6a,7,10,10a-tetrahydro -6,6,9-trimethyl-6H dibenzo[b,d]pyran
(f) JWH 203 1-pentyl-3-(2-chlorophenylacetyl)indole
(g) JWH 210 4-ethylnapthalen-1-yl-(1-pentylindol-3-yl)methanone
(h) AM-694 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole
(i) AM-1221 1-(1-N-methylpipererdin-2-yl)methyl-2-methyl-3-(1-naphthoyl)-6-nitroindole
(j) AM-2201 1-(5-fluoropentyl)-3-(1-naphthoyl)indole
(k) RCS-4 or SR-19 1-pentyl-3-[(4-methoxy)-benzoyl]indole
(l) RCS-8 or SR-18 1-cyclohexylethy-2-methoxyphenylacetyl)indole
(m) JWH-210 (1-pentyl-3-(4-ethylnaphthoyl)indole)
(n) WIN-49,098 (Pravadoline) (4-methoxyphenyl)-[2-methyl-1-(2-morpholin-4-yethyl)indol-3-yl]methanone
(o) WIN-55,212-2 (2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo-1,4-benzoaxazine6- yl)-1-naphthalenylmethanone)
(p) Any of the following synthetic cannabinoids, their salts, isomers, and salts of isomers, unless specifically excepted, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation.
(i) Naphthoylindoles: Any compound containing a 3-(1-naphthoyl) indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-morpholinyl) ethyl group, whether or not further
substituted in the indole ring to any extent and whether or not substituted in the naphthal ring to any extent including, but not limited to, JWH-015, JWH-018, JWH-019, JWH-073, JWH-081, JWH-122, JWH-200, JWH-210, JWH-398 and AM-2201.

(ii) Naphthylmethylindoles: Any compound containing 1H-indol-3-yl-(1-naphthyl) methane structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cyloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-morpholinyl) ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthal ring to any extent including, but not limited to, JWH-015, JWH-018, JWH-019, JWH-073, JWH-081, JWH-122, JWH-200, JWH-210, JWH-398 and AM-2201.

(iii) Naphthylpyrroles: Any compound containing a 3-(1-naphthyl) pyrrole structure with substitution at the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cyloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-morpholinyl) ethyl group, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthal ring to any extent including, but not limited to, JWH-175, JWH-184, and JWH-199.

(iv) Naphthylmethylindenes: Any compound containing a naphthylideneindene structure with substitution at the 3-position of the indene ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cyloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-morpholinyl) ethyl group, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthal ring to any extent including, but not limited to, JWH-176.

(v) Phenylacetylindoles: Any compound containing a 3-phenylacetylindole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cyloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-morpholinyl) ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent including, but not limited to, JWH-203, JWH-250, JWH-251, and RCS-8.

(vi) Phenylacetylicynolphenols: Any compound containing a 3-(hydroxycyclohexyl) phenol structure with substitution at the 5-position of the phenolic ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-morpholinyl) ethyl group, whether or not substituted in the cyclohexyl ring to any extent including, but not limited to, Cannabicyclohexanol (CP 47,497 C8 homologue), CP 47,497 and CP 55,490.

(vii) Benzoylindoles: Any compound containing a 3-(benzoyl) indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cyloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-morpholinyl) ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent including, but not limited to, AM-694, Pravadoline (WIN 48,098), RCS-4, and AM-1241.

(q) UR-144 1-(pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone
(r) XLR11 1-(5-fluoro-pentyl)-1H-indol-3-yl(2,2,3,3-tetramethylcyclopropyl)methanone
(s) AKB48 N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide
(t) Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (PB-22, QUPI)
(u) Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (5-fluoro-PB22; 5F-PB22)
(v) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (AB-FUBINACA)
(w) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (ADB-PINACA)
(x) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (AB-CHMINACA)
(y) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (AB-PINACA)
(z) [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone (THJ-2201)
(aa) FDU-PB-22 IUPAC: 1-Naphthyl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate
(bb) 5-fluoro ABICA IUPAC: N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide
(cc) FUB-144 IUPAC: [1-(4-fluorobenzyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (AKA FUB-UR-144)
(dd) MN-18 IUPAC: N-(1-Naphthyl)-1-pentyl-1H-indazole-3-
carboxamide

(ce) FUB-PB-22 IUPAC: Quinolin-8-yl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate

(ff) ADB-CHMINACA (N-[1-(aminocarbonyl)-2,2-dimethylpropyl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide)

(gg) AMB-FUBINACA (methyl[1-(4-fluorobenzyl)-1H-indazole-3-carbonyl]-L-valinate)

(hh) 5-fluoro-AMB (N-[1-(5-fluoropentyl)-1H-indazol-3-yl]carboxylate, methyl ester)

(ii) 5-fluoro-ADB (N-[1-(5-fluoropentyl)-1H-indazol-3-yl]carboxylate, 3-methyl-D-valine, methyl ester)

(36) Substances determined by the board to have the pharmacological effect of the substance, the risk to the public health by abuse of the substance and the potential of the substance to produce psychic or physiological dependence liability is similar to the substances described in Paragraph (1) or (2) of 30-31-23C NMSA 1978. Substances include but are not limited to:

(a) salvia divinorum

(b) salvinorin A (methyl (2S,4aR,6aR,7R,9S,10aS,10bR)-9-(acetyloxy)-2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxododecahydro-2H-benzo[f]isochromene-7-carboxylate)

(37) 4-methyl-ethylcathinone (4-MEC)

(38) 4-ethyl-methcathinone (4-EMC)

(39) 2-ethylamino-1-phenyl-propan-1-one (ethcathinone)

(40) 3',4'-methylenedioxyethylcathinone (ethlynone)

(41) beta-keto-N-methyl-3,4-benzodioxoylbutanamine (bk-MBDB, butylone)

(42) naphthylpyrovalerone (NRG-1, naphyrone)

(43) N,N-dimethylcathinone (metamfetramone)

(44) alpha-pyrrolidinopropiophenone (alpha-PPP)

(45) alpha-pyrrolidinobutiophenone (α-PBP)

(46) 4'-methoxy-alpha-pyrrolidinopropiophenone (MOPPP)

(47) 4'-methyl-α-pyrrolidinopropiophenone (MPPP)

(48) 3',4'-methylenedioxy-alpha-pyrrolidinopropiophenone (MDPPP)

(49) 3',4'-methylenedioxy-alpha-pyrrolidinobutiophenone (MDPBP)

(50) 4'-methyl-alpha-pyrrolidinobutiophenone (MPBP)

(51) alpha-pyrrolidinovalerophenone (alpha-PVP)

(52) 5,6-methylenedioxy-2-aminooindane (MDAI)

(53) alpha-methylamino-butyrophene (buphedrone)

(54) beta-keto-ethylbenzodioxoylbutanamine (eutylone)

(55) beta-keto-ethylbenzodioxoylpentanamine

(56) beta-keto-methylbenzodioxoylpentanamine (pentydone)

(57) 4-Bromo-2,5-dimethoxyphenethylamine (2c-B, Nexus)

(58) N-hydroxy-3,4-methylenedioxyamphetamine (also known as N-hydroxy-α-methyl-3,4(methylenedioxy)-phenethylamine, and N-hydroxy MDA)

(59) 5-methoxy-N,N-dimethyltryptamine (5-methoxy-3-[2-(dimethylamino)ethyl]indole; 5-MeO-DMT)

(60) 4-methylmethcathinone (Mephedrone)

(61) 3,4-methylenedioxyephedrine (MDPV)

(62) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E)

(63) 2-(2,5-Dimethoxy-4-methylphyl)ethanamine (2C-D)

(64) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2)

(65) 2-[4-(Propylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4)

(66) 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H)

(67) 2-(2,5-Dimethoxynitro-phenyl)ethanamine (2C-N)

(68) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P)

(69) 3,4-Methylenedioxy-N-methylcathinone(Methylone)

(70) Aminorex (2-amino-5-phenyl-2-oxazoline)

(71) Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (PB-22, QUPIC)

(72) Quinolin-8-yl 1-(5-fluoropentyl-1H-indole-3-carboxylate (5-fluro PB22; 5F PB22)
N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluoro-1H-indazole-3-carboxamide (AB-FUBINACA)

N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamine (ADB-PINACA)

Pentedrone

4-fluoro-N-methylcathinone (4-FMC; flephedrone)

3-fluoro-N-methylcathinone (3-FMC)

N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (AB-CHIMINACA)

N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (AB-PINACA)

[1-(5-fluropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone (THJ-2201)

3-methylthiazoledione (3-MMC)

3,4-Trimethylmethcathinone (3,4 DMMC)

3-Methyl-N-ethylcathinone (3-MEC)

2-Methylamino-1-(4-methylphenyl)butan-1-one (4-methylbuphedrone; 4-MeBP)

4-Methylthioamphetamine (4 MTA)

5-Methyl-3,4-methylenedioxoamphetamine (5-Me MDA)

6-benzofuran (6-APB)

4-Methoxyamphetamine (PMA)

2,5-dimethoxy-4-bromophenethylamine (2C-B)

2,5-dimethoxy-4-chlorophenethylamine (2C-C)

4-methyl-2,5-dimethoxyphenethylamine (2C-D)

2,5-dimethoxy-4-ethylphenethylamine, (2C-E, Aquarust, Cindy)

3,4-Dimethyl-2,5-dimethoxyphenethylamine (2C-G)

2,5-Dimethoxy-4-iodophenethylamine (2C-I)

2-[2,5-Dimethoxy-4-(2-fluoroethylthio)phenyl]ethanamine (2C-T21)

2-(8-bromo-2,3,6,7-tetrahydrofuro [2,3-f][1]benzofuran-4-yl)ethanamine (2C-B-FLY)

1-(4-Bromofuro[2,3-f][1]benzofuran-8-yl)propan-2-amine, (Bromo-DragonFLY, 3C-Bromo-Dragonfly, DOB-Dragonfly)

2,5-Dimethoxy-4-bromoamphetamine (DOB)

2,5-Dimethoxy-4-chloroamphetamine (DOC)

2,5-Dimethoxy-4-methylamphetamine (DOM)

2,4,5-trimethoxyamphetamine (TMA2)

2,4,6-trimethoxyamphetamine (TMA6)

6,7-Methylenedioxo-2-aminotetralin (MDAT)

4-acetoxy-N,N-diisopropyltryptamine (4-acetoxy DiPT, ipracetin)

O-Acetylsilicic acid (O-Acetylsilicic acid DM, psilocin)

4-hydroxy-N-methyl-N-ethyltryptamine (4-HO MET, metocin)

4-hydroxy-N-methyl-N-isopropyltryptamine (4-HO MiPT, hats)

5-methoxy-α-methyltryptamine, (5-MeO-MePT, Alpha-O)

N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-methylpropan-2-amine (5-MeO-MePT)

N,N-dimethyltryptamine (DiPT)

Dipropyltryptamine (DPT)

N,N-dialkyl-5-methoxytryptamine (5-MeO-DALT)

3-Methoxyphenethylcldidine (3-MeO PCP)

4-Methoxyphenethylcldidine (4-MeO PCP)

Dizocilpine (MK-801)

Tetrahydroethylen (PCE, perchloroethylene, Perchloroethene, Perc)

3-MeO-2-Oxo-PCE (Methoxetamine)

Phencyclidine, N-(1-phenylcyclohexyl)propanamine (PCP)

1-(2-Thiethyl)cyclohexylpiperididine (Tenocyclidine)

3-Methoxyethylcldidine, N-ethyl-1-(3-methoxyphenyl)cyclohexanamine (3-MeO PCE)

6-ethyl-6-nor-lysergic acid diethylamide (ETH-LAD)

6-allyl-6-nor-LSD (AL-LAD)

10-didehydroergoline-8-carboxamide (PRO-LAD)